MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma by Manisha Bhutani, Myra Robinson, David Foureau, Shebli Atrash, Barry Paul, Fei Guo, Jason M. Grayson, Anna Ivanina-Foureau, Mauricio Pineda-Roman, Cindy Varga, Reed Friend, Christopher J. Ferreri, Xhevahire Begic, Sarah Norek, Tiffany Drennan, Michelle B. Anderson, James T. Symanowski, Peter M. Voorhees, Saad Z. Usmani

Get full text